Department of Epidemiology and Biostatistics, College of Public Health, University of South Florida, Tampa, Florida, USA.
Diabetes Care. 2013 Jul;36(7):1967-73. doi: 10.2337/dc12-1874. Epub 2013 Jan 22.
The role of inflammation in the increased risk of cardiovascular disease in type 1 diabetes is unclear. We examined the association of inflammation and progression of coronary artery calcification (CAC)-a marker of subclinical atherosclerosis-in adults with and without type 1 diabetes.
A nested case-control study was performed within the prospective cohort of the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study. Participants underwent two CAC measurements ~2.5 years apart. Case subjects (n = 204) were those with significant progression of CAC. Control subjects (n = 258) were frequency-matched to case subjects on diabetes status, sex, age, and baseline CAC status. Inflammatory marker assessments were performed on stored blood samples from baseline. A principal components analysis (PCA) was performed and a composite score derived from that analysis. The composite score was constructed by assigning a value of 1 for each PCA component where at least one of the markers exceeded the 75th percentile (range 0-4). Conditional logistic regression was used for the matching strategy.
The first two components of the PCA were modestly (odds ratio 1.38 [95% CI 1.08-1.77] and 1.27 [1.02-1.59], respectively) associated with CAC progression after adjustment for other risk factors. The composite score was more strongly associated with CAC progression for those with elevated markers in three or four of the principal components compared with those with none.
Measures of inflammation were associated with progression of CAC in a population of adults with and without type 1 diabetes.
炎症在 1 型糖尿病患者心血管疾病风险增加中的作用尚不清楚。我们研究了炎症与冠状动脉钙化(CAC)进展的相关性,CAC 是亚临床动脉粥样硬化的标志物,存在于 1 型糖尿病和非 1 型糖尿病患者中。
在前瞻性队列研究——1 型糖尿病冠状动脉钙化(CACTI)研究中,进行了一项嵌套病例对照研究。参与者在大约 2.5 年内接受了两次 CAC 测量。病例组(n=204)为 CAC 显著进展的患者。对照组(n=258)是根据糖尿病状态、性别、年龄和基线 CAC 状态与病例组相匹配的频率匹配患者。在基线时对储存的血液样本进行炎症标志物评估。进行了主成分分析(PCA),并从该分析中得出了一个综合评分。该综合评分通过为每个 PCA 成分赋值来构建,只要至少有一种标志物超过第 75 百分位(范围 0-4),则该成分赋值为 1。使用条件逻辑回归进行匹配策略。
在调整其他危险因素后,PCA 的前两个成分与 CAC 进展适度相关(比值比 1.38 [95%CI 1.08-1.77]和 1.27 [1.02-1.59])。与无升高标志物的患者相比,在三个或四个主要成分中存在升高标志物的患者的复合评分与 CAC 进展的相关性更强。
在 1 型糖尿病和非 1 型糖尿病患者人群中,炎症标志物与 CAC 进展相关。